LUND, Sweden , Oct. 28, 2020 /PRNewswire/ -- Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced that the company will host a webinar to introduce incoming CEO, Patrik Dahlen on Tuesday, November 3 rd , 2020 at 9:00 CET . The webinar will include a Q&A session with CEO, Patrik Dahlen and Chairman, Carl Borrebaeck.
Immunovia previously announced the CEO transition on August 26 th , 2020 ( link to press release ). Patrik Dahlen will join Immunovia as the company's new CEO starting November 1, 2020 . Mats Grahn will assume a position on Immunovia's Board of Directors.
Event Details:
Webinar Introducing New CEO, Patrik Dahlen with Chairman, Carl Borrebaeck
Date: Tuesday, November 3rd, 2020
Time: 9:00 am CET
To join the webinar: Register for Webinar ( link )
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden .
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts , USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com .
CONTACT:
Julie Silbe
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-host-webinar-introducing-new-ceo--patrik-dahlen,c3226694
The following files are available for download:
View original content: http://www.prnewswire.com/news-releases/immunovia-to-host-webinar-introducing-new-ceo-patrik-dahlen-301161447.html
SOURCE Cision AB